Valye reports for unlimited access

CorMedix Inc. develops and commercializes therapeutic products targeting life-threatening conditions. Its flagship product, DefenCath®, is an FDA-approved antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients. Launched in 2024, DefenCath is marketed in inpatient and outpatient settings with significant commercial supply agreements. The company expanded its portfolio in 2025 by acquiring Melinta Therapeutics, adding multiple anti-infective products and a cardiovascular drug, broadening its hospital and clinic market reach. CorMedix pursues additional indications for its products, including clinical trials for DefenCath in total parenteral nutrition patients and prophylaxis indications for REZZAYO®. Manufacturing is outsourced to FDA-approved third-party suppliers, with ongoing efforts to reduce costs and onshore production. The company maintains a strong liquidity position and reported profitability in recent quarters.

MGSD is a Nevada-incorporated public company with subsidiaries in Samoa, Hong Kong, and Beijing, China. Its primary operating subsidiary, Tongzhilian, focuses on cultural tourism services, including education and family tours, and the distribution of Chinese cultural and creative products. The company plans to expand into organizing and managing arts expositions. Tongzhilian designs tours and cultural content, working with third-party operators for logistics, and markets through a network of sales agents. Product sales include tea, alcohol, gift cards, and plans for proprietary cultural product lines targeting youth markets. Arts expositions involve participatory cultural presentations and are marketed through the same sales network. The company holds necessary operating licenses in Beijing and is subject to regulatory compliance in China. MGSD operates in a fragmented and competitive market with various cultural tourism and product competitors. Seasonality affects its tourism and exposition sales, while product sales are steady year-round. The company does not maintain insurance for property or liability risks. MGSD is subject to multiple tax jurisdictions and is an emerging growth company under U.S. regulations. It faces operational risks including cybersecurity and data privacy challenges. Financially, the company reported revenue and net loss figures for the latest quarter ending June 30, 2026, with liquidity ratios indicating limited short-term financial flexibility.

Aimei Health Technology Co., Ltd. is a special purpose acquisition company (SPAC) that has not commenced operations or generated revenue. Its primary activities have been organizational, preparing for an IPO, and seeking a target for a business combination. The company earns non-operating income from interest on cash held in a Trust Account established for public shareholders. It incurs expenses related to being a public company and due diligence for business combinations. The company’s liquidity is primarily derived from IPO proceeds held in the Trust Account. The company has experienced a working capital deficit and reported a net loss in the latest quarter. Internal controls have material weaknesses, with remediation efforts planned. The company’s recent business combination agreement with United Hydrogen was terminated, impacting its share price.

Pyxis Oncology, Inc. is a clinical-stage biotechnology company specializing in antibody-drug conjugates (ADCs) for oncology indications. Its lead candidate, micvotabart pelidotin (MICVO), targets the extradomain-B of fibronectin (EDB+FN), a splice variant expressed in the tumor extracellular matrix but minimally in normal tissues. MICVO's mechanism involves targeted delivery of a microtubule inhibitor payload to the tumor microenvironment, inducing cancer cell death through direct cytotoxicity, a bystander effect, and immunogenic cell death. The company is advancing MICVO in clinical trials as monotherapy and in combination with pembrolizumab for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. Pyxis has completed Phase 1 dose escalation and is conducting dose expansion studies, with preliminary data showing encouraging response rates and tolerability. The company also pursues strategic collaborations and aims to leverage its biologics technology platforms. Financially, Pyxis reported revenue of $13.9 million for 2025 and a net loss of $25.3 million for Q2 2026, with a cash position supporting ongoing development activities.

Tapestry Inc is a global luxury goods company operating iconic brands Coach and kate spade new york. The company’s business model centers on direct-to-consumer retail and e-commerce channels, supported by wholesale and licensing businesses. Coach represents the majority of sales, with Kate Spade contributing a smaller but significant portion. The company’s strategy focuses on building emotional connections with consumers, particularly targeting younger demographics, driving fashion innovation, and expanding global presence with emphasis on Greater China and Europe. Manufacturing is outsourced to independent partners primarily in Asia, with strong quality and social compliance oversight. Distribution is managed through a network of company-operated and third-party fulfillment centers globally. Tapestry invests heavily in marketing and digital technology, including AI and machine learning, to enhance consumer engagement and operational efficiency. The company owns and actively protects its intellectual property portfolio. Seasonal trends affect sales and inventory cycles, with higher sales typically in the second fiscal quarter. Financially, Tapestry reported strong profitability and liquidity as of fiscal 2026 year-end.

AleAnna, Inc. operates as a natural gas resource company delivering critical natural gas supplies to Europe through onshore conventional natural gas exploration and renewable natural gas development in Italy. The company holds a 33.5% working interest in the Longanesi field, one of Italy's largest modern natural gas discoveries, and owns additional conventional natural gas properties and exploration prospects supported by proprietary 3D seismic imaging. AleAnna launched a renewable natural gas business in 2023 focused on carbon negative biomethane derived from animal and agricultural waste, acquiring three biogas plants in Italy in 2024. The company’s conventional natural gas production began in March 2025, with a gas sale agreement with Shell Energy Europe Limited. AleAnna benefits from Italian government incentives for biomethane production and maintains a management team with extensive upstream energy experience. The company is headquartered in Dallas, Texas, with offices in Rome and Milan, Italy.

Idaho Strategic Resources, Inc. operates primarily in the mining sector, focusing on the exploration, development, and production of precious and strategic metals. The company’s key asset is the Golden Chest Mine located in Idaho, USA, along with other exploration properties. It employs conventional flotation processing to produce bulk sulfide flotation concentrate sold to smelters in Asia. The company’s financial position as of mid-2026 shows substantial assets, including cash, investments in US Treasury notes, and mineral properties, with relatively low liabilities. The company reported positive operating income and net income for the first half of 2026. The business model centers on advancing exploration projects to commercial production and generating cash flow from mineral sales.

TRANSUITE.ORG INC. (TRSO) operates in AI, Web3, and new-energy infrastructure sectors. Its business includes strategic consulting, enterprise technology services, and infrastructure-related solutions. The company owns subsidiaries such as Solan (Shenzhen) Technology Co., Ltd. and Goldfinch-Chong (Fuzhou) Technology Co., Ltd., the latter being a leading provider of intelligent electric two-wheeler charging and management solutions in China. TRSO has entered into strategic cooperation agreements to expand AI-enabled charging infrastructure and is developing scalable Web3 and digital asset platforms through partnerships and acquisitions. The company reported modest revenue in 2025 but incurred significant net losses primarily due to non-cash stock-based compensation and goodwill impairment. Management is focused on revenue growth, strategic expansion, market development, technology advancement, and capital structure management to improve financial position and operational scale [S1][S2].

Galata Acquisition Corp. II operates as a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands in June 2025. Its business model centers on raising capital through an IPO and private placements to fund an initial business combination with one or more target companies. The company has not commenced operations or generated revenues and focuses on identifying acquisition targets primarily in energy, financial technology, real estate, and technology sectors, though it may consider other industries or geographies. The management team has experience in public and private investments through affiliation with Callaway Capital Management LLC. The company’s IPO raised $172.5 million, with proceeds held in a trust account pending consummation of a business combination. The company must complete the business combination by September 22, 2027, or face liquidation and return of funds to shareholders. The company’s governance includes a board of four directors with diverse backgrounds. Dilution risks exist for public shareholders due to founder shares and warrants held by sponsors and management.

Presidio Production Co is a publicly traded company on the New York Stock Exchange under the ticker FTW since March 2026. The company has engaged in strategic acquisitions such as the Canyon Creek purchase and has initiated an AI-focused Asset Intelligence Group to enhance its operational capabilities. It has also declared its first dividend as a public company, indicating a focus on shareholder returns. The company regularly communicates its financial results and business developments through earnings calls and press releases.

BioVie Inc. is a clinical-stage biopharmaceutical company developing innovative drug therapies for neurological and neurodegenerative disorders and advanced liver disease. The company acquired NeurMedix's assets including bezisterim (NE3107), an investigational oral small molecule targeting inflammation-driven insulin resistance and neuroinflammation, with potential applications in Parkinson's disease, Alzheimer's disease, and Long COVID. Bezisterim has demonstrated positive Phase 2b clinical trial results in early-stage Parkinson's disease, showing statistically significant reductions in neuroinflammatory biomarkers and improvements in motor and non-motor symptoms. The company is conducting a Phase 2 trial in Long COVID neurological symptoms and has conducted Phase 2 and Phase 3 trials in Alzheimer's disease, though the Phase 3 trial was underpowered due to protocol deviations at some sites. BioVie is also developing BIV201, a continuous infusion terlipressin formulation for treating ascites related to liver cirrhosis, which has FDA Fast Track and Orphan Drug designations. Phase 2 data showed significant reductions in ascites fluid volume. The company holds patents on novel liquid formulations of terlipressin and methods of treating ascites. Financially, as of June 30, 2026, BioVie had $8.98 million in cash and equivalents, a current ratio of 3.59, and reported a net loss of $22.07 million for the fiscal year.

iAnthus Capital Holdings, Inc. is a holding company with a broad portfolio of wholly owned subsidiaries operating primarily in the cannabis industry across multiple U.S. states. The company is focused on optimizing its portfolio by divesting non-core assets and concentrating resources on growth markets such as Florida, Maryland, New Jersey, Massachusetts, and New York, while maintaining a retail presence in Arizona. The company faces significant liquidity challenges and has reported substantial losses, raising concerns about its ability to continue as a going concern. Its financial reporting follows U.S. GAAP with detailed accounting policies for assets, leases, and inventory.

BioStem Technologies, Inc. is a publicly reporting company with recent quarterly financial disclosures through its 10-Q filing as of August 12, 2026. The company reported revenues and net losses for the quarter ended June 30, 2026. Specific details about its sector, industry, and business operations are not disclosed in the available data. The company’s liquidity position shows current liabilities slightly exceeding current assets as of the latest quarter.

VenHub Global, Inc. develops and operates autonomous retail stores under the VenHub brand, combining AI, robotics, and advanced sensors to provide a fully autonomous shopping experience available 24/7. The company’s Smart Stores feature robotic picking, bagging, delivery, inventory tracking, and a mobile app for customers and store owners. VenHub operates through four subsidiaries focused on manufacturing, software services, intellectual property management, and company-owned store operations. The company holds a portfolio of 25 patent applications protecting its technology. VenHub is currently in the development stage, having begun revenue generation in 2025, and is focused on expanding its technology capabilities and store footprint.

21Shares Solana ETF is a Delaware statutory trust formed in 2024 that issues shares representing fractional interests in SOL tokens held by the Trust. It is a passive investment vehicle designed to track the CME CF Solana-Dollar Reference Rate, adjusted for expenses and liabilities, and may reflect staking rewards. The Trust's SOL assets are held by multiple custodians, and shares trade on the Cboe BZX Exchange. The Sponsor manages the Trust, paying operating expenses from a 0.21% annual fee on NAV and receiving a share of staking rewards. Shares are created and redeemed in blocks of 10,000 by authorized participants. The Trust is not registered as an investment company or commodity pool and does not actively trade SOL except for expenses, redemptions, or termination. The NAV is calculated daily based on the pricing benchmark.

InterPrivate Investment Partners V, Inc. is a publicly reporting entity with limited publicly disclosed information about its sector, industry, or detailed business operations. The company files quarterly reports with the SEC, with the latest filing dated August 12, 2026. Financial data available includes current assets, liabilities, and net income for the quarter ended June 30, 2026. The company maintains strong liquidity as indicated by a high current ratio. No further operational or strategic details are disclosed in the available data.

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology. The company’s proprietary platform includes a microbial library of approximately 1,500 unique bacterial strains, augmented by AI and machine learning technologies to identify drug-like molecules. Azitra specializes in genetically engineering Staphylococcus epidermidis and other skin commensal bacteria to deliver therapeutic proteins directly to the skin, bypassing the natural skin barrier. The company’s lead product candidates target rare and chronic skin diseases such as Netherton syndrome (ATR-12), EGFR inhibitor-associated rash (ATR-04), and ichthyosis vulgaris (ATR-01). Azitra has established academic partnerships and holds exclusive licenses to advanced genetic engineering technologies to expand its pipeline. The company has not yet commenced commercial operations and is currently advancing its clinical programs and platform development.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing treatments for schizophrenia and other central nervous system disorders. The company's primary focus is on brilaroxazine, its only advanced product candidate, which is undergoing clinical trials including a planned Phase 3 RECOVER-2 trial. The company has no products approved for commercial sale and depends on regulatory approval and successful commercialization of brilaroxazine. Another product candidate, RP1208, is in pre-clinical development but currently receives limited resources. The company was delisted from Nasdaq in May 2026 due to non-compliance with minimum bid price requirements and now trades on the OTCQB Venture Market, which has affected stock liquidity and market presence. Financially, as of June 30, 2026, the company held nearly $20 million in cash and equivalents and reported a net loss for the quarter, reflecting ongoing investment in clinical development and operations.

BitGo Holdings, Inc. provides a comprehensive digital asset platform designed for institutional clients to securely store, manage, and utilize digital assets. The platform is structured into four layers: self-custody wallet solutions leveraging patented multi-sig and MPC technology; qualified custody solutions with fiduciary duties and regulatory compliance; liquidity and prime brokerage services including staking, lending, and trading; and infrastructure-as-a-service offerings such as Stablecoin-as-a-Service and Crypto-as-a-Service. BitGo operates a federally chartered national trust bank regulated by the OCC and holds a significant Bitcoin treasury as part of its financial strategy. The company serves over 5,320 clients and 1.2 million users across more than 100 countries, supporting over 1,770 digital assets and managing approximately $81.6 billion in Assets on Platform as of December 31, 2025. BitGo’s revenue is derived from digital asset sales, staking, subscription and service fees, stablecoin services, and interest income. The company maintains strong regulatory compliance, security audits, and insurance coverage for client assets.

Blue Water Acquisition Corp. III operates as a special purpose acquisition company (SPAC). The company’s primary business model involves raising capital through an initial public offering to acquire or merge with an existing business. Specific details about target industries, operational activities, or revenue streams are not disclosed in the available filings. The company’s financial position as of June 30, 2026, shows significant current liabilities relative to current assets, reflecting the typical capital structure of a SPAC prior to completing a business combination.

Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for atopic dermatitis and eczema, with its lead candidate GX-03 undergoing Phase 2 clinical trials. The company has publicly reported interim data from these trials and has adjusted its trial design based on this data. Turn Therapeutics completed its Nasdaq public listing in October 2025, which was accompanied by significant stock price movement. Financial disclosures as of June 30, 2026, indicate the company maintains liquidity slightly above its short-term liabilities but continues to operate at a net loss. The company is classified as a smaller reporting company and has not disclosed new risk factors in its latest quarterly filing.

Holistic Asset Finance Group Co., Ltd. is a Nevada-incorporated company trading on OTC markets under the symbol HAFG. It operates mainly through its subsidiary Wombat Australia Holdings Pty Ltd, offering digital marketing and video production services focused on short-form video content across Singapore, Taiwan, Australia, and Hong Kong, with expansion into other Asian markets. The company also engages in product sales and export trading, primarily of Australian-branded health and wellness products, though this segment has diminished in revenue contribution. The company has a small workforce distributed across Australia, China, and Taiwan, and emphasizes customer-centric flexibility and regional market knowledge. It faces intense competition in both its digital marketing and health product sectors and operates with limited liquidity and recent net losses.

Ashford Hospitality Trust, Inc. is a real estate investment trust specializing in direct hotel investments in the United States. Its portfolio consists mainly of upscale and upper upscale full-service hotels branded under Hilton, Hyatt, Marriott, and Intercontinental Hotel Group. The company owns 68 operating hotel properties with over 16,600 rooms. It operates through an advisory agreement with Ashford LLC and contracts hotel management companies to operate its hotels, with Remington Hospitality managing the majority. The company’s investment strategy targets hotels with revenue per available room generally less than twice the national average, seeking both current income and appreciation. It also pursues other lodging-related investments such as mezzanine financing and sale-leaseback transactions. The company faces significant indebtedness and liquidity challenges, with a substantial portion of debt maturing within one year and a deficit in stockholders’ equity. Dividends on common stock are not expected in the foreseeable future, and preferred dividends have been suspended but may be paid when feasible. The company’s business is subject to competitive pressures, regulatory requirements, and risks related to its advisory and management agreements.

Evolution Global Acquisition Corp is a Cayman Islands-incorporated blank check company (SPAC) formed in June 2025 to effect a business combination with one or more businesses. The company completed its IPO in November 2025, raising $240 million, which is held in a trust account invested in U.S. government securities. The company has not commenced operations or generated revenues and incurs expenses related to being a public company and pursuing acquisition targets. The management team includes experienced professionals in finance, mining, and natural resources sectors. The company’s financial position as of mid-2026 shows cash and liquidity ratios consistent with its SPAC status. The company’s shares have redemption rights classified as temporary equity. The company may receive working capital loans from related parties to finance transaction costs, potentially convertible into warrants.

Virgin Galactic Holdings Inc operates in the aerospace and defense industry, focusing on commercial human spaceflight. The company offers suborbital spaceflight experiences designed for safety, comfort, and a superior astronaut experience. Its spaceflight system includes a reusable rocket-powered spaceship launched from a custom-built twin-fuselage carrier aircraft. Virgin Galactic has exclusive use of Spaceport America, a commercial spaceflight launch site with favorable conditions. The company has completed several commercial and research flights, including missions funded by government agencies such as NASA and the Italian government. It is developing next-generation spaceships with increased passenger capacity and flight frequency, aiming to enhance operational scale. Virgin Galactic also provides research flight opportunities and engineering services leveraging its aerospace expertise.

U.S. GoldMining Inc. is a U.S.-based exploration stage company focused solely on the Whistler Project, a gold-copper exploration project in Alaska's Yentna Mining District. The company is a subsidiary of GoldMining Inc., which holds a majority stake. The Whistler Project comprises multiple mineral systems and has undergone extensive exploration activities including drilling and metallurgical testing. The company completed its IPO in 2023 and is listed on Nasdaq. It announced a Preliminary Economic Assessment for the Whistler Project in March 2026. The company maintains strong liquidity but reported a net loss in the most recent quarter. It also disclosed potential legal risks related to warrant share issuances.

Humacyte, Inc. is a biotechnology company focused on developing bioengineered blood vessels and related products for vascular access and other medical applications. The company’s product pipeline includes the ATEV (Arteriovenous Graft) and Symvess, targeting dialysis access and vascular trauma treatment. Humacyte has been advancing clinical development and preparing for commercialization, including adding nephrology advisors to support market entry. The company operates with a focus on innovation in regenerative medicine and bioengineered therapeutics.

Soulpower Acquisition Corp. is a Cayman Islands exempted company operating as a Special Purpose Acquisition Company (SPAC) listed on the New York Stock Exchange under the ticker SOUL. The company entered into a business combination agreement with SWB Holdings, a Cayman Islands exempted company, to form a new public financial services conglomerate. The combined entity plans to operate as SOUL WORLD BANK™, a licensed international financial institution offering diverse financial products including a stablecoin-denominated AI bank with tokenized asset yield offerings. The business combination values SWB Holdings at approximately $8.1 billion pre-money based on asset contributions. Soulpower has secured a $5 billion committed equity facility to support post-closing capital needs. The company has issued unsecured promissory notes for working capital, some of which are forgiven upon consummation of the business combination. As of June 30, 2026, the company reported current assets of $3.13 million and current liabilities of $4.37 million, with a current ratio below 1, indicating liquidity constraints. The company has reported net income of $1.92 million for the period ending June 30, 2026. Directors have resigned in 2026 without disclosed disagreements. Risk factors disclosed in the 2025 annual report remain applicable with no material changes reported.

Atea Pharmaceuticals, Inc. focuses on developing orally administered antiviral therapies for serious viral infections, leveraging a proprietary nucleos(t)ide platform. Its lead HCV regimen combines bemnifosbuvir, a nucleotide analog NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor, designed as a pan-genotypic, protease inhibitor-free, short-duration treatment with low drug-drug interaction risk and no food effect. The company is conducting two Phase 3 trials globally: C-BEYOND (US/Canada) and C-FORWARD (outside North America). Enrollment completed in both trials by mid-2026, with topline results anticipated in 2026 and NDA submission planned for 2027. AT-587, targeting chronic HEV infection in immunocompromised patients, is in preclinical development with clinical trials anticipated to start mid-2026. Atea does not own manufacturing facilities and relies on contract manufacturers. It currently lacks commercial infrastructure and may seek partnerships for commercialization, especially outside the US. The company has incurred significant operating losses and has no approved products or revenue to date.

FinWise Bancorp operates as a bank holding company headquartered in Utah, conducting its business through FinWise Bank, a Utah state-chartered bank. The company’s business model centers on originating loans in various sectors including SBA 7(a), residential and commercial real estate, commercial leasing, and strategic programs with third-party loan origination platforms. FinWise leverages technology and fintech partnerships to offer banking as a service (BaaS) and payment solutions nationwide, including Mastercard co-branded credit cards and API-driven banking services. The company’s funding primarily comes from deposits, including brokered and institutional deposits, and it maintains a focus on managing credit risk through diversified loan portfolios and allowance for credit losses methodologies. FinWise’s financial performance in recent years shows growth in loan originations, net interest income, and non-interest income, alongside increased provisions for credit losses reflecting portfolio expansion and risk management.

Crown Reserve Acquisition Corp. I is a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands in April 2025. The company’s business model is to raise capital through an IPO and private placement to fund a future business combination with one or more target companies. The IPO raised $172.5 million, which was placed in a Trust Account invested in U.S. government securities. The company’s units include Class A ordinary shares, warrants, and rights, which trade separately on Nasdaq. The company has a 12-month period from IPO closing to complete a business combination, extendable to 15 months upon signing a definitive agreement. The management team brings extensive experience across multiple sectors and a broad network to source and evaluate potential targets. The company currently has no operations or full-time employees and focuses solely on identifying and completing a business combination.

Crown Crafts Inc is a consumer products company focused on infant, toddler, and juvenile products. It operates through two wholly-owned subsidiaries, offering a diverse product range including bedding, toys, bibs, diaper bags, feeding products, and nursery accessories. The company markets products under its own trademarks and licensed brands, with a significant portion of sales derived from licensed products, notably under agreements with Disney. Sales are primarily direct to a wide range of retailers, including mass merchants and internet retailers. Manufacturing is largely outsourced to contract manufacturers, predominantly in China, with foreign offices overseeing production and quality. The company faces challenges from tariffs and global trade policies affecting sourcing costs. It employs a national sales force and independent representatives to market its products. Financially, the company reported net income and maintains liquidity with a current ratio of 3.2 as of June 28, 2026. Key risks include reliance on major customers and licenses, tariff exposure, and industry competition. [S1][S2]

American Exceptionalism Acquisition Corp. A operates as a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands. The company raised gross proceeds of $345 million through its IPO in September 2025, issuing Class A ordinary shares at $10.00 per share. The capital raised is held in a trust account pending the identification and completion of a business combination with a target operating company. The company has not disclosed any operating segments or target businesses. It is listed on the New York Stock Exchange under the ticker AEXA and is classified as an emerging growth company.

Sizzle Acquisition Corp. II is a Special Purpose Acquisition Company (SPAC) incorporated in July 2024 in the Cayman Islands. Its business model is to identify and complete a Business Combination with one or more target companies, primarily in sectors where its management team has experience, including restaurant, hospitality, food and beverage, retail, consumer, food technology, real estate (proptech), mining, professional sports teams, airlines, and technology. The company completed its IPO in April 2025, raising $230 million, which is held in a trust account until a Business Combination is consummated. The company has not yet selected a target and has no operating revenues. The management team has a track record of working together and experience in identifying acquisition targets. The company’s investment criteria focus on large market opportunities, strong competitive positions, experienced management teams, and potential for stable free cash flow. The company faces competition from other SPACs and investment entities and has a limited period (24 months from IPO) to complete a Business Combination, subject to possible extension with shareholder approval.

Resideo Technologies, Inc. (ticker: REZI) is a global technology-driven manufacturer and distributor specializing in sensing and control products and solutions that enhance comfort, security, energy use, and smart living in residential and commercial spaces. The company’s product portfolio includes temperature and humidity controls, water and air solutions, smoke and carbon monoxide detectors, security products, video cameras, cloud infrastructure, and related software. Resideo serves approximately 100,000 professional contractors and installers worldwide and has products installed in over 150 million spaces globally. The company operates through two segments: Products and Solutions, and ADI Global Distribution, a specialty distributor of low-voltage products. In August 2026, Resideo completed a tax-free spin-off of the ADI Global Distribution segment, resulting in a more focused company with a higher leverage profile due to retained indebtedness and loss of ADI’s revenue and cash flow contributions. Manufacturing operations span multiple countries including the U.S., Mexico, and several European and Asian locations. The company faces competitive pressures from a range of global and regional providers and is subject to various regulatory and environmental compliance requirements. Resideo manages market risks related to interest rates, currency exchange, and commodity prices through hedging and operational strategies [S1][S2].

Journey Medical Corp is a pharmaceutical company specializing in the commercialization of FDA-approved prescription drugs for dermatological conditions in the United States. The company operates as a controlled subsidiary of Fortress Biotech, Inc. Its product portfolio includes treatments for rosacea, acne, primary axillary hyperhidrosis, fungal infections, pruritus, and wound healing. Key products include Emrosi, an oral minocycline extended release capsule for rosacea; Qbrexza, a topical cloth for hyperhidrosis; Accutane, an oral isotretinoin for severe acne; and topical minocycline foams Amzeeq and Zilxi. The company also markets legacy products such as Exelderm, Targadox, Luxamend, and an Anti-itch Product. Journey Medical's strategy focuses on commercial execution, lifecycle management, out-licensing, and growth through acquisitions and licensing. The company maintains a commercial sales force and leverages proprietary drug delivery technologies. It is subject to FDA regulatory oversight and holds patents extending through 2030 to 2039 for its products.